|Articles|March 11, 2008

NCPA issues statement on bill that would add human growth hormone to Schedule III

NCPA comments on bill that would classify human growth hormone as Schedule III substance.

The National Community Pharmacists Association has issued a comment on Senate Bill S877/House Bill 4911. The MAGIC Foundation, a nonprofit group devoted to growth disorders in children, is against Senate Bill S877/

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Latest CME

$Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists$

NCPA issues statement on bill that would add human growth hormone to Schedule III

Related Content

Study Links Live Flu Vaccine With Rise in Pneumococcal Disease

How Pharmacy Advocacy Is Inherent in Pharmacist Duties

FAQ: What the RFI on Vaccine Categories Means for Pharmacists

FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products

Early Antiviral Therapy Cuts Influenza Hospitalization Risk Children

Latest CME

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

Trending on Drug Topics

FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products

FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies

FDA Approves Stelara for Pediatric Ulcerative Colitis

Experts Urge Pneumococcal Vaccination for Older Patients With Chronic Respiratory Disease

FAQ: What the RFI on Vaccine Categories Means for Pharmacists